• Hepatitis B: A global strategy for developing a cure

    While the cure of hepatitis C today is not a medical problem for almost all patients, but at most, a health policy problem, the elimination or at least drug-free control of the HB virus can still only be achieved in a minority of chronically infected patients.

  • HBV: Increased risk of cancer even with low viral load

    Even under a cutoff of less than 2000 IU/ml HBV DNA, infected patients have an increased risk of developing hepatocellular carcinoma. This is probably due to the integration of the hepatitis B virus (HBV) into the human genome.

  • Alarming UK data: Fatty liver diseases in adolescents

    A study from Great Britain shows that in a population-based cohort, almost every fifth person examined had a fatty liver with an average age of 24 years. In addition, many patients had already developed liver fibrosis.

  • Hepatitis C: consistently high cure rates for all patients

    Today, almost all HCV-infections can be successfully treated in clinical routine - even those patients who have not responded to pre-therapies or who have shown failure in therapy.

  • NAFLD/NASH meets "Leaky Gut"

    The effect of a disturbed intestinal barrier on the liver was investigated in a pilot study by a Japanese research group, which presented its results at the International Liver Congress (ILC) 2019.

  • Fatty liver disease therapies, a top topic at the ILC

    Obeticholic acid (OCA) effectiveness in the treatment of non-alcoholic fatty liver disease NAFLD/NASH has been demonstrated for the first time in an interim analysis of the Phase-III REGENERATE study.

  • Theranostics: Functional imaging with PCa

    Behind this word lies a new method that combines diagnostics and therapy. In prostate cancer, a PSMA ligand, such as that used in PET/CT, is linked to a radioisotope such as 177 lutetium. This achieves site-specific tumor therapy.

  • HPV infections in men: farewell to fertility?

    With more than 200 known genotypes the human papillomaviruses are not only dermatologically relevant. HPV infection must be regarded as a systemic infection that can also be detected in the testicles or ejaculate of men. But does it also affect fertility?

  • Focal therapy failure: A walk on thin ice

    Focal Therapy (FT) for prostate cancer is considered as an organ-preserving surgical technique with few side effects. However, there is no extensive evidence-based data for its effectiveness and it is still regarded as an experimental procedure.

  • Jumping-breast phenomenon: sufficiently well known, little recorded

    The jumping breast phenomenon is well known in cosmetic surgery but there is hardly any literature about it. In oncological breast surgery, the problem has even been mostly ignored so far, although the deformation of the breast is sometimes serious and the patients suffer considerably from it.

  • Breast cancer in women: Therapeutic perspectives from a translational perspective

    The kick-off day of the 10th International Charité Mayo Conference, staged a keynote lecture by Adrian Lee from Pittsburgh, USA, who has a key role in the design of precision medicine.

  • Antibiotics: Is a solution of the resistance problem in sight?

    Overuse, misuse and also the almost exponential use of antibiotics in animal production contribute to antibiotic resistance. Important medications may no longer be usable in the future. The search for antibiotics alternatives has therefore long ago begun.

  • More often than thought: the forgotten stent

    The placement of a stent is a routine task for urologists worldwide. The responsibility to remove this stent also rests on their shoulders. Statistically, however, about 13% of stents are forgotten - with far-reaching consequences for the patients and beyond.

  • Testosterone deficiency increases prostate cancer risk

    Testosterone administration is contraindicated in PCa patients even after radical prostatectomy. But more recent findings in hypogonadal men hint at a slow rehabilitation of testosterone substitution.

  • Urogenital tuberculosis often remains undetected

    Urogenital TB is often overlooked. In regions with high TB prevalence, it is "treated" as a classic UTI. UTIs may mask urogenital tuberculosis frequently, and doctors should be reminded of this scenario.

  • Nephrolithiasis: There are news

    Nephrolithiasis is a frequently treated disease in urology, assumed to have no further room for groundbreaking innovations. However, causal research and the vacuum-assisted mini-percutaneous nephrolithotomy (vmPCNL) hint at new developments.

  • Drug interactions are hardly avoidable in HIV treatment

    Drug interactions are almost impossible to avoid in the care of HIV patients, said David Back, University of Liverpool. The risk for polypharmacy and thus for interactions increases with age due to increased comorbidities and physiological changes.

  • Obesity, a rising problem in HIV treatment

    Obesity has many consequences for the health of those affected. John R. Koethe, Vanderbilt University Medical Center, Nashville, TN, USA, presented the current state of research at the CROI 2019.

  • Multi-resistant tuberculosis: studies are taking too long

    With only a few studies available, the current WHO recommendations are mainly based on observations. Jennifer Furin, Harvard Medical School, USA, presented current developments in MDR-TB treatments.

  • Latency-absorbing substances for the shock-and-kill strategy

    Latent HI viruses are the first target of the so-called shock-and-kill strategy. As part of this strategy, latency is eliminated by Latency Reversing Agents (LRAs).

  • 77 |
  • 78 |
  • 79 |
  • 80 |
  • 81 |
  • 82 |
  • 83 |
  • 84 |
  • 85 |
  • 86 |
  • 87 |